SG Americas Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

SG Americas Securities’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,400	Closed	-$32K	–	3248
2025 Q4	$32K	Hold	15,400	–	–	﹤0.01%	3413
2025 Q3	$116K	Hold	15,400	–	–	﹤0.01%	3019
2025 Q2	$119K	Hold	15,400	–	–	﹤0.01%	2559
2025 Q1	$44K	Hold	15,400	–	–	﹤0.01%	3263
2024 Q4	$80K	Buy	+15,400	New	+$1.03M	﹤0.01%	2798
2021 Q1	–	Sell	-30,000	Closed	-$60K	–	3291
2020 Q4	$60K	Hold	30,000	–	–	﹤0.01%	3123
2020 Q3	$300K	Buy	+30,000	New	+$3.04M	﹤0.01%	1939
2018 Q1	–	Sell	-56,300	Closed	-$40K	–	3255
2017 Q4	$40K	Hold	56,300	–	–	﹤0.01%	3005
2017 Q3	$151K	Buy	+56,300	New	+$4.97M	﹤0.01%	2832
2017 Q1	–	Sell	-14,000	Closed	-$130K	–	3278
2016 Q4	$130K	Hold	14,000	–	–	﹤0.01%	2675
2016 Q3	$90K	Hold	14,000	–	–	﹤0.01%	3096
2016 Q2	$234K	Hold	14,000	–	–	﹤0.01%	2045
2016 Q1	$235K	Hold	14,000	–	–	﹤0.01%	2103
2015 Q4	$126K	Buy	+14,000	New	+$1.46M	﹤0.01%	2303
2015 Q3	–	Sell	-14,000	Closed	-$70K	–	2124
2015 Q2	$70K	Hold	14,000	–	–	﹤0.01%	2431
2015 Q1	$105K	Buy	+14,000	New	+$1.48M	﹤0.01%	2251

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

SG Americas Securities's BMRN Position: Q2 2026 in Review

SG Americas Securities reduced its BioMarin Pharmaceuticals (BMRN) stake by 44% in Q2 2026, selling an estimated $3.5M and leaving 83,024 shares worth $4.75M. The position accounts for ﹤0.01% of the portfolio, ranked #1113.

SG Americas Securities first reported a position in BMRN in Q3 2013 and has held it in 50 quarters since. The position peaked at $21.3M in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

SG Americas Securities held 83,024 shares of BioMarin Pharmaceuticals worth $4.75M as of Q2 2026.
SG Americas Securities sold 63,939 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $3.5M.
BioMarin Pharmaceuticals made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1113 holding.
SG Americas Securities first reported a position in BioMarin Pharmaceuticals in Q3 2013 and has held it in 50 quarters since.
SG Americas Securities's BioMarin Pharmaceuticals position peaked at $21.3M in Q4 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.